
Mallory L Hacker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7898251/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Deep brain stimulation in early-stage Parkinson disease. Neurology, 2020, 95, e393-e401.	1.1	75
2	Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. Neurology, 2018, 91, e463-e471.	1.1	55
3	Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 1177-1183.	2.2	41
4	Impact of Tremor on Patients With Early Stage Parkinson's Disease. Frontiers in Neurology, 2018, 9, 628.	2.4	30
5	Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson's Disease. Journal of Parkinson's Disease, 2016, 6, 125-131.	2.8	26
6	BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics, 2020, 17, 1785-1795.	4.4	12
7	Deep brain stimulation in early stage Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 347-348.	2.2	10
8	Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 89-94.	2.8	10
9	Prevalence of Spasticity in Nursing Home Residents. Journal of the American Medical Directors Association, 2020, 21, 1157-1160.	2.5	8
10	A comparative evaluation of telehealth and direct assessment when screening for spasticity in residents of two long-term care facilities. Clinical Rehabilitation, 2021, 35, 589-594.	2.2	8
11	Deep brain stimulation in early stage Parkinson's disease may reduce the relativeÂrisk of symptom worsening. Parkinsonism and Related Disorders, 2016, 22, 112-113.	2.2	7
12	Recruitment and Retention in Clinical Trials of Deep Brain Stimulation in Early-Stage Parkinson's Disease: Past Experiences and Future Considerations. Journal of Parkinson's Disease, 2018, 8, 421-428.	2.8	6
13	BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease. Neuromodulation, 2022, 25, 846-853.	0.8	6
14	Early subthalamic nucleus deep brain stimulation in Parkinson's disease reduces long-term medication costs. Clinical Neurology and Neurosurgery, 2021, 210, 106976.	1.4	6
15	Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson's Disease Is Not Associated with Increased Body Mass Index. Parkinson's Disease, 2017, 2017, 1-4.	1.1	4
16	A Simple Bedside Screening Tool for Spasticity Referral. Clinical Interventions in Aging, 2020, Volume 15, 655-662.	2.9	4
17	Deep Brain Stimulation in Early-Stage Parkinson's Disease: Patient Experience after 11 Years. Brain Sciences, 2022, 12, 766.	2.3	3
18	The Minimum Data Set: An Opportunity to Improve Spasticity Screening. Journal of the American Medical Directors Association, 2021, 22, 608-612.	2.5	1

MALLORY L HACKER

#	Article	IF	CITATIONS
19	Exploring the presence of multiple abnormal non-motor features in patients with cervical dystonia. Journal of Clinical Neuroscience, 2021, 94, 315-320.	1.5	1
20	Long-Term Care Resident Awareness and Interest in Spasticity Treatments. Geriatrics (Switzerland), 2021, 6, 21.	1.7	0
21	Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes. Neurology, 2021, 96, 592-592.	1.1	0
22	Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes. Neurology, 2021, 96, 591.1-591.	1.1	0
23	Enhancing Performance of a Spasticity Screening Tool Using the Minimum Data Set. Journal of the American Medical Directors Association, 2021, , .	2.5	0